Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03705819 · ClinicalTrials.gov registry record · Early Phase 1
Exploratory Evaluation of [11C]-NOP46
A Early Phase 1 study of Chronic Pain, sponsored by Columbia University.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT03705819 is a Early Phase 1 study of Chronic Pain that has completed, run by Columbia University. The registered enrollment target is 10 participants, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state.
The verdict
NCT03705819, a Early Phase 1 study of Chronic Pain, has completed, sponsored by Columbia University.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open-label, single center design. In the first stage, five (5) healthy individuals will receive a microdose (10µg) of \[11C\]-NOP46, immediately followed by whole body positron emission tomography (PET)/computed tomography (CT) to determine dosimetry and perform an initial safety evaluation of the radiotracer. If no toxicities develop, then the investigation will move to the second stage, in which thirty (30) patients with chronic pain will receive a microdose of \[11C\]-NOP46 followed by PET/CT of region of interests.
Conditions Studied
Interventions
- DRUG [11C]-NOP46
- RADIATION PET/CT scan
Study Locations (1)
New York
- Columbia University Irving Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2019-03-25 |
| Est. Completion | 2023-10-30 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03705819
The ClinicalTrials.gov registry entry for NCT03705819 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 772-participant average among 301 other Chronic Pain trials with a reported enrollment target (99% lower). The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Pain appearing as the primary indexed condition, and to 2 interventions - of which [11C]-NOP46 is the first listed.
NCT03705819 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT03705819 about?
NCT03705819 is a clinical study titled "Exploratory Evaluation of [11C]-NOP46". This is an open-label, single center design. In the first stage, five (5) healthy individuals will receive a microdose (10µg) of \[11C\]-NOP46, immediately followed by whole body positron emission tomography (PET)/computed tomography (CT) to determine dosimetry and perform an initial safety evaluati...
What is the current status of trial NCT03705819?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 10 participants. The study started on 2019-03-25. Estimated completion is 2023-10-30.
What conditions does trial NCT03705819 study?
This clinical trial studies the following conditions: Chronic Pain.
What interventions are being tested in trial NCT03705819?
The interventions under investigation include: [11C]-NOP46 (DRUG), PET/CT scan (RADIATION).
Who is sponsoring clinical trial NCT03705819?
This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03705819 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Pain
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Cannabidiol in Opioid Use Disorder and Chronic Pain
RECRUITING · Early Phase 1
-
Safety and Efficacy of Mesenchymal Stem Cells Associated With Chronic Pancreatitis Pain
RECRUITING · Early Phase 1
-
Improving Pain Management Via Spinal Cord Stimulation and Blood Pressure Reduction
ACTIVE NOT RECRUITING · Early Phase 1
-
Immunologic Response to Negative Cognition in Persons With Chronic Pain
COMPLETED · Early Phase 1
-
Managing Chronic Pain in Veterans With Substance Use Disorders
COMPLETED · Early Phase 1
-
Non-Opioid Pramipexole and Pain
COMPLETED · Early Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.